GlassScriptPhysician profile
Susan Phung
NPI 1548581622
$3,788.55
in general payments reported to CMS, 2019-2025
21 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $868 · 2023: $875 · 2024: $1,146 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,009.99 | 2021-2024 | |
| Glaxosmithkline, LLC. | $592.47 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $490.10 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.38 | 2021-2025 | Jardiance, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $223.06 | 2021-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $190.49 | 2022-2024 | Verquvo |
| Pfizer INC. | $170.65 | 2021-2024 | |
| Optinose US, INC. | $155.18 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $147.79 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $124.10 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.07 | 2021-2022 | |
| Baxter Healthcare | $79.22 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $55.64 | 2023-2024 | Wakix |
| Philips North America LLC | $30.28 | 2022-2024 | (Ak6) Vest Therapy |
| Abbott Laboratories | $23.64 | 2023 | Cardiomems |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.73 | 2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $16.98 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.90 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Esperion Therapeutics, INC. | $14.57 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.31 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.